Showing results (11-20 of 88) with videos related to

Sort By:
Pageof 9
Chemmedchem|January 3, 2019
TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible StructureMaria Kalyukina, Yuliana Yosaatmadja, Martin J Middleditch, et al.
Current Pharmaceutical Design|June 8, 2002
Antiangiogenic, bioreductive and gene therapy approaches to the treatment of hypoxic tumoursVirginia A McNally, Adam V Patterson, Kaye J Williams, et al.
Biochemical Pharmacology|October 24, 2018
Evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative vector for bacterial-directed enzyme-prodrug therapyJasmine V E Chan-Hyams, Janine N Copp, Jeff B Smaill, et al.
Cancer Research|October 3, 2008
Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104Shie-Chau Liu, G-One Ahn, Mitomu Kioi, et al.
Biochemical Pharmacology|July 25, 2007
Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxiaChris P Guise, Anderson T Wang, Anke Theil, et al.
Journal of the American Chemical Society|February 10, 2010
Characterization of radicals formed following enzymatic reduction of 3-substituted analogues of the hypoxia-selective cytotoxin 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine)Sujata S Shinde, Andrej Maroz, Michael P Hay, et al.
Biochemical Pharmacology|April 20, 2006
Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylatorG-One Ahn, K Jane Botting, Adam V Patterson, et al.
Biotechnology Letters|August 28, 2020
Directed evolution of the B. subtilis nitroreductase YfkO improves activation of the PET-capable probe SN33623 and CB1954 prodrugMichelle H Rich, Abigail V Sharrock, Amir Ashoorzadeh, et al.
Cancer Chemotherapy and Pharmacology|December 17, 2009
A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumorsMichael B Jameson, Danny Rischin, Mark Pegram, et al.
Radiation Research|May 26, 2007
Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustardsWilliam R Wilson, Kevin O Hicks, Susan M Pullen, et al.
Pageof 9